Gentronix Expands Specialist Sales Team in US and Europe
News Feb 17, 2012
Gentronix has expanding its sales teams with the appointments of Dorothy Zelent as Director of North American Operations, and Simon Johns as European Sales Director.
Reporting to Commercial Director, Dr. Steve Beasley, the company’s latest appointments lead the commercialization efforts in their respective territories.
With an extensive background in molecular biotechnology, Dorothy Zelent has over 10 years’ experience in academic and pharmaceutical research.
A graduate of the University of Pennsylvania, she previously conducted research into diabetes drug discovery before joining GlaxoSmithKline as a senior scientist in cardiovascular drug discovery.
Dorothy also brings broad project management skills to the role from previous positions as Director of Business Development for a number of clinical research technology companies.
European Sales Director, Simon Johns, has an impressive technical background in microbiology and genetics, as well as 20+ years’ international commercial experience supporting clients in the pharmaceutical, biotechnology and chemical sectors.
With his early research activities including the development of genotoxicity imaging systems, Simon has since worked extensively within the pre-clinical toxicology sector for several major global CROs in both Europe and the US.
Dr. Steve Beasley, Commercial Director at Gentronix comments, “Both Dorothy and Simon are experienced commercial professionals with a wealth of life sciences expertise, and we welcome them to the Gentronix team. We’re sure they will both make a significant contribution to the company’s strategy of growing the business, not only through the commercialization of our proprietary technologies, but also by expanding our service provision and continuing to establish collaborations in existing and new sectors.”
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE
Commonly Prescribed Painkillers: What Can be Done to Reduce Risk of Obesity and Sleep Deprivation?News
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.READ MORE
Safer Opioids: Separating Pain Relieving Properties from Dangerous Side EffectsNews
A group of researchers, led by Dr. Laura Bohn at The Scripps Research Institute, may have found a way to make opioids safer by separating the drugs' pain relieving effects from their most dangerous side effect, respiratory suppression, which, in very severe cases, causes patients to stop breathing and to die.READ MORE